Recent Finacing
Recent Raise
SinoMab is a clinical-stage biopharma developing therapeutic monoclonal antibodies including anti-CD22, operating R&D and production facilities in Shenzhen, Haikou, Suzhou, with Phase III autoimmune and oncology trials.
Focus Areas
Recent Investors
Funding round
Investors
